Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board
22 Dezember 2009 - 12:30PM
PR Newswire (US)
NEW YORK, Dec. 22 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical technology company testing its
proprietary treatment method for primary and metastatic cancers to
the liver, announced today that Professor Riccardo Lencioni has
joined the Company's Scientific Advisory Board, effective
immediately. "We formed our Scientific Advisory Board in 2008 to
advance the development of our Delcath PHP System(TM) with insight
from the leading experts in regional cancer therapies," said Eamonn
Hobbs, President and CEO of Delcath. "Professor Lencioni is well
known to us at Delcath. He has extensive expertise in treating
liver cancers and is a pioneer in the emerging field of
interventional oncology. We are confident that he will have a
palpable impact on the clinical and regulatory success of our core
technology, ongoing R&D, and other key scientific initiatives."
Professor Lencioni is an Associate Professor of Radiology at the
University of Pisa in Italy and the Director of the Division of
Diagnostic Imaging and Intervention at Pisa University Hospital. He
is Chairman of the Membership Committee of the Cardiovascular and
Interventional Radiological Society of Europe, and Chairman of the
Programme Committee of the European Conference on Interventional
Oncology. He is also a member of the Steering Committee of the
World Conference on Interventional Oncology, and was a founder of
the International Liver Cancer Association, in which he also acts
as a member of the Governing Board. Professor Lencioni has been a
Visiting Professor at 20 different European, American and Asian
universities. Professor Lencioni earned his medical degree with
honors from the University of Pisa, where he is board certified in
Radiology and Gastroenterology. Having completed two fellowships in
Interventional Radiology, he has served as a faculty member in
various residency programs, including Radiology, Surgery and
Gastroenterology. Professor Lencioni has edited seven books and has
authored 135 articles in peer-reviewed international journals and
40 book chapters in textbooks of Radiology, Gastroenterology and
Surgery. He has been an invited or honorary lecturer for more than
400 international meetings and conferences. Delcath's Scientific
Advisory Board now has five members. In addition to Professor
Lencioni, the board includes Professor Alexander M.M. Eggermont,
MD, PhD, from the Erasmus University Medical Center in The
Netherlands; Doctor Douglas L. Fraker, from the University of
Pennsylvania School of Medicine; Doctor Larry Kvols, from the H.
Lee Moffitt Cancer Center & Research Institute in Tampa,
Florida; and Doctor Leonard B. Saltz, from the Memorial
Sloan-Kettering Cancer Center and the Weill College of Medicine in
New York. About Delcath Systems, Inc. Delcath Systems Inc. is a
medical device company specializing in cancer treatment. The
Company is testing a proprietary, patented drug delivery system for
the treatment of liver cancers. Delcath's novel drug delivery
platform is testing the delivery of ultra-high doses of anti-cancer
drugs to the liver while preventing these high doses of drug from
entering the patient's bloodstream. The Company maintains a broad
intellectual property portfolio on a worldwide basis including the
U.S., Europe, Asia and Canada. For more information, please visit
the Company's website at http://www.delcath.com/. The Private
Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf.
This news release contains forward-looking statements, which are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to,
uncertainties relating to our ability to successfully complete
Phase III clinical trials and secure regulatory approval of our
current or future drug-delivery system and uncertainties regarding
our ability to obtain financial and other resources for any
research, development and commercialization activities. These
factors, and others, are discussed from time to time in our filings
with the Securities and Exchange Commission. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to
reflect events or circumstances after the date they are made.
DATASOURCE: Delcath Systems, Inc. CONTACT: Investors, Doug Sherk or
Stacey Fisher, +1-415-896-6820, or Media, Steve DiMattia,
+1-646-201-5445, all of EVC Group, for Delcath Systems, Inc. Web
Site: http://www.delcath.com/
Copyright